Literature DB >> 29942788

A rare case of giant renal angiomyolipoma in a woman with tuberous sclerosis.

Charalampos Fragkoulis1, Konstantinos Stasinopoulos1, Georgios Theocharis1, Georgios Stathouros1, Georgios Papadopoulos1, Akrivi Kostopoulou2, Mariana Bethany-Michaelides2, Konstantinos Ntoumas1.   

Abstract

Entities:  

Keywords:  Giant; Renal angiomyolipoma; Tuberous sclerosis

Year:  2018        PMID: 29942788      PMCID: PMC6011037          DOI: 10.1016/j.eucr.2018.06.006

Source DB:  PubMed          Journal:  Urol Case Rep        ISSN: 2214-4420


× No keyword cloud information.

Introduction

Angiomyolipoma (AML) is the most common benign renal tumor diagnosed in clinical practice. It is composed of a mix of dysmorphic blood vessels, smooth muscle components, and mature adipose tissue. It mainly occurs sporadically affecting 0.3–3% of the general population but it is encountered quite often in patients suffering from tuberous sclerosis, Von Hippel-Lindau syndrome and neurofibromatosis type 1. The aim of this case report is to present a very rare case of a giant AML in a woman treated in our department in an open surgical approach.

Case report

A 35-year old female was referred to our department with complaints of abdominal distention, constipation and palpable abdominal mass. Patient had been diagnosed during childhood with tuberous sclerosis (TS) and presented with full manifestation of the disease including facial angiofibromas, mental retardation, epilepsy and retinal lesions. Clinical examination revealed a giant palpable mass occupying the whole abdomen (Fig. 1). A contrast enhanced computed tomography was performed revealing a left renal mass with diameter of 40cm with radiological characteristics of AML (Fig. 2). Renal scan showed a 20% partial contribution of the left kidney to total renal function.
Fig. 1

Abdominal distention due to AML.

Fig. 2

AML as shown in Computed Tomography.

Abdominal distention due to AML. AML as shown in Computed Tomography. Subsequently, patient underwent left nephrectomy in an open transabdominal approach. Due to close correlation of the AML with the spleen and intraoperative hemorrhage, a splenectomy was performed simultaneously. As it was not technically feasible to extract the whole AML intact, we removed it in three pieces with the largest being 30 cm × 26 cm X 10 cm in diameter. The total weight was 7200gr (Fig. 3). Pathological report confirmed the diagnosis of AML (Fig. 4). Patient was transfused with two units of red blood cells during the operation. No complications were noted postoperatively, peritoneal drainage was removed on 5th day and the patient was discharged on 8th day with normal renal function.
Fig. 3

The whole bulk of AML divided in 3 pieces.

Fig. 4

AML with classic triphasic histology: an admixture of mature fat, thick walled blood vessels and smooth muscle (HE x25).

The whole bulk of AML divided in 3 pieces. AML with classic triphasic histology: an admixture of mature fat, thick walled blood vessels and smooth muscle (HE x25).

Discussion

Although AML is quite rare among general population and generally remaining small and asymptomatic, it is quite often encountered in patients suffering from tuberous sclerosis. It is estimated that 26%–80% of patients diagnosed with tuberous sclerosis present with AML, while almost 80% of patients diagnosed with AML do not have TS. In addition, patients with TS present AML in younger age, with larger tumors. Clinical manifestations of AML include abdominal pain, distention and haematuria, although small masses are often asymptomatic. The most serious and dangerous complication with high mortality rates is spontaneous bleeding into the retroperitoneal space from pathological vessels, referred to as Wünderlich syndrome, straightly associated with diameter. Close monitoring is the best option for most cases of AML and indications for surgical treatment include tumor size > 4cm and presence of symptoms at the time of diagnosis. If a surgical approach is decided, nephron-sparing surgery is the method of choice whenever technically feasible. In other cases nephrectomy is performed. The decision for open approach, laparoscopic of robot-assisted surgery is based on surgeon's experience. The open approach for nephrectomy in our patient was preferred mostly due to the massive size of the AML and the close correlation with the spleen. To our knowledge, this AML is one of the largest reported in literature and the biggest reported to be treated in a Greek hospital., Giant AML of proximal size has been reported by Katz and Poster, where the mass measured 45 cm × 20 cm × 15 cm and weighed 3500 gr. In review of the literature, the heaviest AML is the one reported by Taneja et al. with total weight of 7500 gr.
  5 in total

1.  Wünderlich's syndrome: causes, diagnosis and radiological management.

Authors:  G Albi; L del Campo; D Tagarro
Journal:  Clin Radiol       Date:  2002-09       Impact factor: 2.350

2.  Massive renal angiomyolipoma in tuberous sclerosis.

Authors:  D S Katz; R B Poster
Journal:  Clin Imaging       Date:  1997 May-Jun       Impact factor: 1.605

3.  Giant renal angiomyolipoma: unusual cause of huge abdominal mass.

Authors:  Rajesh Taneja; Dig Vijay Singh
Journal:  J Clin Imaging Sci       Date:  2013-11-28

Review 4.  Renal angiomyolipoma: a radiological classification and update on recent developments in diagnosis and management.

Authors:  Masahiro Jinzaki; Stuart G Silverman; Hirotaka Akita; Yoji Nagashima; Shuji Mikami; Mototsugu Oya
Journal:  Abdom Imaging       Date:  2014-06

5.  Spontaneous rupture of a giant renal angiomyolipoma-Wunderlich's syndrome: Report of a case.

Authors:  Panagiotis Nikolaos Chronopoulos; Georgios Nikolaos Kaisidis; Christos Konstantinos Vaiopoulos; Dragana Milosav Perits; Michail Nikolaos Varvarousis; Apostolos Vasilios Malioris; Elissabeth Pazarli; Ioannis Konstantinos Skandalos
Journal:  Int J Surg Case Rep       Date:  2015-12-17
  5 in total
  1 in total

1.  Giant renal angiomyolipoma: A case report.

Authors:  Maher Al-Hajjaj
Journal:  Urol Case Rep       Date:  2021-05-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.